Logo

ZTEK

Zentek Ltd.

ZTEK

Zentek Ltd. • NASDAQ
$0.76 ▼ -0.44% (-0.00)
Market Cap $76.79 M
52w High $1.84
52w Low $0.62
Dividend Yield 0%
P/E -12.58
Volume 60.91K
Outstanding Shares 101.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $6.204K ▼ $2.08M ▲ $-2.391M ▼ -38.543K% ▼ $-0.02 ▼ $-2.168M ▼
Q1-2025 $57.797K ▼ $1.83M ▼ $-1.362M ▲ -2.357K% ▼ $-0.013 ▲ $-1.167M ▲
Q4-2024 $813.596K ▲ $2.646M ▲ $-1.84M ▲ -226.116% ▲ $-0.018 ▲ $-1.882M ▲
Q3-2024 $37.718K ▲ $2.481M ▲ $-2.602M ▲ -6.898K% ▲ $-0.026 ▲ $-2.425M ▲
Q2-2024 $15.692K $-218.783K $-3.045M -19.405K% $-0.03 $-2.667M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $1.335M ▼ $16.87M ▼ $5.184M ▲ $11.686M ▼
Q1-2025 $2.889M ▲ $18.482M ▲ $4.494M ▲ $13.988M ▼
Q4-2024 $121.481K ▼ $18.396M ▲ $3.647M ▲ $14.749M ▲
Q3-2024 $1.032M ▼ $13.221M ▼ $1.965M ▼ $11.255M ▼
Q2-2024 $2.169M $15.712M $1.986M $13.726M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.391M ▼ $-1.209M ▼ $-323.235K ▼ $-22.129K ▼ $-1.554M ▼ $-1.532M ▼
Q1-2025 $-1.362M ▲ $-1.175M ▲ $2.314M ▲ $1.628M ▲ $2.767M ▲ $-1.228M ▲
Q4-2024 $-1.84M ▲ $-1.283M ▲ $-89.398K ▼ $8.709K ▲ $-1.363M ▲ $-1.283M ▲
Q3-2024 $-2.602M ▼ $-1.754M ▼ $499.375K ▲ $-196.076K ▼ $-1.45M ▼ $-1.755M ▼
Q2-2024 $-2.25M $-1.351M $-22.187K $2.114M $9.328K $-1.351M

Five-Year Company Overview

Income Statement

Income Statement Zentek is still essentially a pre‑revenue company. Over the past several years it has not generated meaningful sales and has consistently posted accounting losses. The losses themselves are relatively small and have recently been narrowing after a larger dip a few years ago, but the business is clearly still in the development and ramp‑up phase rather than in a mature, profitable stage. Future income statement health hinges almost entirely on whether its graphene technologies can move from testing and pilots into repeat commercial orders.

Balance Sheet

Balance Sheet The balance sheet is very light, reflecting a small, early‑stage company. Zentek has a modest pool of assets and shareholder equity, with no financial debt, which reduces balance‑sheet risk. On the other hand, its cash position has come down from earlier levels and now looks thin relative to ongoing losses. That combination—no leverage but limited cash—means the company’s financial strength depends on its ability to either secure partnerships, raise fresh capital, or both, to support its plans.

Cash Flow

Cash Flow Cash flows from operations have been consistently negative, though on a relatively small scale, which is typical for a research‑heavy, pre‑revenue business. There is little to no spending on large physical assets, so free cash flow is negative mainly because of operating costs rather than big investments in plants or equipment. The key question is how long current resources and any new funding can support this cash burn while the company pushes its technologies toward meaningful commercial adoption.

Competitive Edge

Competitive Edge Zentek’s competitive angle rests on its intellectual property and its control of a unique graphite deposit, rather than on size or market share. Its ZenGUARD and ZenARMOR coatings, along with patents and patent applications, create barriers for direct copycats. The wholly owned Albany graphite deposit provides a potential long‑term supply of high‑purity material, which could anchor cost and quality advantages. However, Zentek is very small compared with global chemical, materials, and healthcare players. It faces the classic challenges of an innovator: proving performance at scale, securing regulatory and customer acceptance, and competing against established technologies and well‑funded rivals. Its partnership‑driven commercialization strategy is intended to offset its limited scale but also means its success is tied to the strength and execution of those partners.

Innovation and R&D

Innovation and R&D Innovation is the core of Zentek’s story. The company has built a portfolio of graphene‑based technologies such as ZenGUARD (antimicrobial coatings for masks and air filters) and ZenARMOR (corrosion‑resistant coatings), and is exploring applications in fire‑retardant gels, ice‑repellent surfaces, fuel additives, conductive inks, and advanced protective materials. It is also involved in aptamer‑based rapid detection for pathogens, which ties more directly into healthcare diagnostics. Historically, the business has been research‑led, and management has signaled a shift toward commercialization while maintaining a broad pipeline. This creates multiple potential avenues for future revenue, but also concentrates risk in unproven technologies that must clear technical, regulatory, and market hurdles before they become durable cash generators.

Summary

Zentek is a small, early‑stage advanced materials and healthcare technology company whose financials show a classic pre‑commercial profile: no meaningful revenue yet, recurring but modest losses, negative operating cash flow, and a lean asset base with no debt but limited cash. The investment story is dominated by its graphene‑based IP, the Albany graphite deposit, and a range of potential applications from air filtration and corrosion protection to fire safety and diagnostics. The upside case depends on turning these innovations into scalable, recurring commercial contracts, largely via partnerships. The key risks revolve around funding needs, execution on commercialization, regulatory approvals, and competition from larger, established players and alternative technologies. Overall, this is a high‑uncertainty, innovation‑driven situation where financial outcomes will be driven far more by technology and market adoption milestones than by current reported numbers.

NEWS

November 25, 2025 · 8:30 AM UTC

Zentek Announces Appointment of Mohammed Jiwan as Chief Executive Officer

Read more

November 21, 2025 · 4:30 PM UTC

Zentek Receives CRA Notice of Reassessment for 2019

Read more

November 5, 2025 · 8:30 AM UTC

Zentek Announces the Development of a New Graphite Gel-Based Fire-Retardant Product and an Exclusive Licence with Altek Advanced Materials Inc. for the US Market

Read more

October 22, 2025 · 5:34 PM UTC

Zentek Announces Closing of Non-Brokered Private Placement of Units for Gross Proceeds of $2,479,227

Read more

October 20, 2025 · 10:30 AM UTC

Zentek Announces Upsizing of Non-Brokered Private Placement to up to $2,500,000

Read more